5 Things You Don't Want to Overlook in MannKind Corporation's Q3 Update
When a company reports a big loss that's worse than what analysts expected, you expect the stock to go down. That's exactly what happened with MannKind Corporation (NASDAQ: MNKD). After the market closed on Tuesday, the biotech reported a third-quarter loss of $32.9 million, or $0.31 per share -- well below analysts' estimates. And MannKind stock opened on Wednesday 10% below its previous close. That's not surprising.
This loss and the market reaction don't mean much at all for what the future might hold for MannKind. There were several things in the company's third-quarter update that will likely impact what happens next, though. Here are five things that you don't want to overlook -- one of them that indicates things will get worse for MannKind, and four that could mean things will get better.
Image source: Getty Images.
Source: Fool.com
